1
|
Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, Graff SL, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard TJ, Rugo HS, Sammons SL, Schwartzberg LS, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Gal-Yam EN. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol 2023; 34:1141-1151. [PMID: 38072514 DOI: 10.1016/j.annonc.2023.09.3104] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 08/24/2023] [Accepted: 09/13/2023] [Indexed: 12/18/2023] Open
Abstract
BACKGROUND Acquired estrogen receptor alpha (ER/ESR1) mutations commonly cause endocrine resistance in ER+ metastatic breast cancer (mBC). Lasofoxifene, a novel selective ER modulator, stabilizes an antagonist conformation of wild-type and ESR1-mutated ER-ligand binding domains, and has antitumor activity in ESR1-mutated xenografts. PATIENTS AND METHODS In this open-label, randomized, phase II, multicenter, ELAINE 1 study (NCT03781063), we randomized women with ESR1-mutated, ER+/human epidermal growth factor receptor 2 negative (HER2-) mBC that had progressed on an aromatase inhibitor (AI) plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) to oral lasofoxifene 5 mg daily or IM fulvestrant 500 mg (days 1, 15, and 29, and then every 4 weeks) until disease progression/toxicity. The primary endpoint was progression-free survival (PFS); secondary endpoints were safety/tolerability. RESULTS A total of 103 patients received lasofoxifene (n = 52) or fulvestrant (n = 51). The most current efficacy analysis showed that lasofoxifene did not significantly prolong median PFS compared with fulvestrant: 24.2 weeks (∼5.6 months) versus 16.2 weeks (∼3.7 months; P = 0.138); hazard ratio 0.699 (95% confidence interval 0.434-1.125). However, PFS and other clinical endpoints numerically favored lasofoxifene: clinical benefit rate (36.5% versus 21.6%; P = 0.117), objective response rate [13.2% (including a complete response in one lasofoxifene-treated patient) versus 2.9%; P = 0.124], and 6-month (53.4% versus 37.9%) and 12-month (30.7% versus 14.1%) PFS rates. Most common treatment-emergent adverse events with lasofoxifene were nausea, fatigue, arthralgia, and hot flushes. One death occurred in the fulvestrant arm. Circulating tumor DNA ESR1 mutant allele fraction (MAF) decreased from baseline to week 8 in 82.9% of evaluable lasofoxifene-treated versus 61.5% of fulvestrant-treated patients. CONCLUSIONS Lasofoxifene demonstrated encouraging antitumor activity versus fulvestrant and was well tolerated in patients with ESR1-mutated, endocrine-resistant mBC following progression on AI plus CDK4/6i. Consistent with target engagement, lasofoxifene reduced ESR1 MAF, and to a greater extent than fulvestrant. Lasofoxifene may be a promising targeted treatment for patients with ESR1-mutated mBC and warrants further investigation.
Collapse
Affiliation(s)
- M P Goetz
- Department of Oncology, Mayo Clinic, Rochester.
| | - N A Bagegni
- Division of Oncology, Washington University School of Medicine, St. Louis, USA
| | - G Batist
- Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
| | - A Brufsky
- University of Pittsburgh Medical Center-Magee Women's Hospital, Pittsburgh
| | - M A Cristofanilli
- Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York
| | - S Damodaran
- The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston
| | | | - G F Fleming
- The University of Chicago Medical Center, Chicago
| | - W J Gradishar
- Division of Hematology/Oncology, Northwestern University, Chicago
| | - S L Graff
- Lifespan Cancer Institute/Legorreta Cancer Center at Brown University, Providence
| | | | - E Hamilton
- Sarah Cannon Research Institute/Tennessee Oncology, Nashville
| | - S Lavasani
- Division of Hematology and Medical Oncology, UC Irvine, Orange
| | | | - T O'Connor
- Roswell Park Comprehensive Cancer Center, Department of Medicine, Buffalo
| | - T J Pluard
- Saint Luke's Cancer Institute, Kansas City
| | - H S Rugo
- Department of Medicine (Hematology/Oncology), University of California San Francisco, San Francisco
| | - S L Sammons
- Dana Farber Cancer Institute, Harvard Medical School, Boston
| | | | - D G Stover
- Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus
| | - G A Vidal
- Breast Oncology Division, West Cancer Center, Memphis
| | - G Wang
- Medical Oncology, Miami Cancer Institute at Baptist Health, Miami, USA
| | - E Warner
- Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - R Yerushalmi
- Rabin Medical Center, Beilinson Hospital, Petah Tikva, Tel-Aviv University, Tel-Aviv, Israel
| | | | | | - E N Gal-Yam
- Breast Oncology Institute, Sheba Medical Center, Ramat Gan, Israel
| |
Collapse
|
2
|
Bhalla K, Job S, Mitra S, Harrison JE, Mbugua LW, Neki K, Gutierrez H, Balasubramaniyan R, Winer M, Vos T, Hamilton E. Assessing discrepancies in estimates of road traffic deaths in Brazil. Inj Prev 2023; 29:412-417. [PMID: 37208005 DOI: 10.1136/ip-2023-044871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 04/30/2023] [Indexed: 05/21/2023]
Abstract
INTRODUCTION The First UN Decade of Action for Road Safety (2011-2020) ended with most low/middle-income countries (LMICs) failing to reduce road traffic deaths. In contrast, Brazil reported a strong decline starting in 2012. However, comparisons with global health statistical estimates suggest that official statistics from Brazil under-report traffic deaths and overestimate declines. Therefore, we sought to assess the quality of official reporting in Brazil and explain discrepancies. METHODS We obtained national death registration data and classified deaths to road traffic deaths and partially specified causes that could include traffic deaths. We adjusted data for completeness and reattributed partially specified causes proportionately over specified causes. We compared our estimates with reported statistics and estimates from the Global Burden of Disease (GBD)-2019 study and other sources. RESULTS We estimate that road traffic deaths in 2019 exceeded the official figure by 31%, similar to traffic insurance claims (27.5%) but less than GBD-2019 estimates (46%). We estimate that traffic deaths have declined by 25% since 2012, close to the decline estimated by official statistics (27%) but much more than estimated by GBD-2019 (10%). We show that GBD-2019 underestimates the extent of recent improvements because GBD models do not track the trends evident in the underlying data. CONCLUSION Brazil has made remarkable progress in reducing road traffic deaths in the last decade. A high-level evaluation of what has worked in Brazil could provide important guidance to other LMICs.
Collapse
Affiliation(s)
- Kavi Bhalla
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Soames Job
- World Bank Global Road Safety Facility, World Bank, Washington, DC, USA
| | - Sudeshna Mitra
- World Bank Global Road Safety Facility, World Bank, Washington, DC, USA
| | | | | | - Kazuyuki Neki
- World Bank Global Road Safety Facility, World Bank, Washington, DC, USA
| | - Hialy Gutierrez
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | | | - Mercer Winer
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Theo Vos
- Institute for Health Metrics and Evaluation, Seattle, Washington, USA
| | - Erin Hamilton
- Institute for Health Metrics and Evaluation, Seattle, Washington, USA
| |
Collapse
|
3
|
Neki K, Gutierrez H, Mitra S, Temesgen AM, Mbugua LW, Balasubramaniyan R, Winer M, Roberts J, Vos T, Hamilton E, Naghavi M, Harrison JE, Job S, Bhalla K. Addressing discrepancies in estimates of road traffic deaths and injuries in Ethiopia. Inj Prev 2022; 29:234-240. [PMID: 36600523 DOI: 10.1136/ip-2022-044704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Accepted: 11/11/2022] [Indexed: 12/12/2022]
Abstract
BACKGROUND There are large discrepancies between official statistics of traffic injuries in African countries and estimates from the Global Burden of Disease (GBD) study and WHO's Global Status Reports on Road Safety (GSRRS). We sought to assess the magnitude of the discrepancy in Ethiopia, its implications and how it can be addressed. METHODS We systematically searched for nationally representative epidemiological data sources for road traffic injuries and vehicle ownership in Ethiopia and compared estimates with those from GBD and GSRRS. FINDINGS GBD and GSRRS estimates vary substantially across revisions and across projects. GSRRS-2018 estimates of deaths (27 326 in 2016) are more than three times GBD-2019 estimates (8718), and these estimates have non-overlapping uncertainty ranges. GSRRS estimates align well with the 2016 Demographic and Health Survey (DHS-2016; 27 838 deaths, 95th CI: 15 938 to 39 738). Official statistics are much lower (5118 deaths in 2018) than all estimates. GBD-2019 estimates of serious non-fatal injuries are consistent with DHS-2016 estimates (106 050 injuries, 95th CI: 81 728 to 130 372) and older estimates from the 2003 World Health Survey. Data from five surveys confirm that vehicle ownership levels in Ethiopia are much lower than in other countries in the region. INTERPRETATION Inclusion of data from national health surveys in GBD and GSRRS can help reduce discrepancies in estimates of deaths and support their use in highlighting under-reporting in official statistics and advocating for better prioritisation of road safety in the national policy agenda. GBD methods for estimating serious non-fatal injuries should be strengthened to allow monitoring progress towards Sustainable Development Goal target 3.6.
Collapse
Affiliation(s)
- Kazuyuki Neki
- World Bank Global Road Safety Facility, Washington, DC, USA
| | - Hialy Gutierrez
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Sudeshna Mitra
- World Bank Global Road Safety Facility, Washington, DC, USA
| | - Awoke M Temesgen
- Institute for Health Metrics and Evaluation, Seattle, Washington, USA
| | | | | | - Mercer Winer
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Jaeda Roberts
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Theo Vos
- Institute for Health Metrics and Evaluation, Seattle, Washington, USA
| | - Erin Hamilton
- Institute for Health Metrics and Evaluation, Seattle, Washington, USA
| | - Mohsen Naghavi
- Institute for Health Metrics and Evaluation, Seattle, Washington, USA
| | - James E Harrison
- Research Center for Injury Studies, Flinders University, Bedford Park, South Australia, Australia
| | - Soames Job
- World Bank Global Road Safety Facility, Washington, DC, USA
| | - Kavi Bhalla
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| |
Collapse
|
4
|
Moore K, Bouberhan S, Hamilton E, Liu J, O'Cearbhaill R, O'Malley D, Papadimitriou K, Schröder D, Van Nieuwenhuysen E, Yoo SY, Peterman M, Goncalves P, Schmidt T, Zhu M, Lowy I, Uldrick T, Miller E. 197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
5
|
Yeku O, D. Shepard, Patel M, Fleming G, Vaena D, Rasco D, Chmielowski B, Sharma M, Hamilton E, Sullivan R, Papadopoulos K, Izar B, Cojocaru G, Ophir E, Ferre P, Dumbrava E. 159P COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant epithelial ovarian cancer. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
6
|
Lu M, Shaw P, Richardson D, Hamilton E, Bernardo P, Bradshaw C, Tolcher A, Mosher R. Archival vs fresh tumor samples for assessing the gene expression of NaPi2b and immune-related genes in the Phase 1b study of Upifitamab Rilsodotin (UpRi) in platinum-resistant ovarian cancer. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01033-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
7
|
Hamilton E, Meisel J, Alemany C, Virginia B, Lin N, Wesolowski R, Mathauda-Sahota G, Makower D, Lawrence J, Faltaos D, Mitri Z, Sabanathan D, Clark D, Pluard T, Hui R, McCarthy N, Patel M. Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826). Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00896-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Jhaveri K, Han H, Dotan E, Oh DY, Ferrario C, Tolcher A, Lee KW, Liao CY, Kang YK, Kim Y, Hamilton E, Spira A, Patel N, Karapetis C, Rha S, Boyken L, Woolery J, Bedard P. 460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
9
|
Hamilton E, Hoskins H, Whitfield C, Helme D. P.28 Midwifery confidence in intrapartum epidural neurological monitoring: a survey and interventions. Int J Obstet Anesth 2022. [DOI: 10.1016/j.ijoa.2022.103324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Hamilton E, Hoskins H, Whitfield C, Helme D. P.138 Monitoring of neurological blockade after epidural insertion on delivery suite. Int J Obstet Anesth 2022. [DOI: 10.1016/j.ijoa.2022.103434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Mbugua LW, Mitra S, Neki K, Gutierrez H, Balasubramaniyan R, Winer M, Roberts J, Vos T, Hamilton E, Naghavi M, Harrison JE, Job S, Bhalla K. Estimates of road traffic deaths in Tanzania. Inj Prev 2022; 28:422-428. [PMID: 35459744 DOI: 10.1136/injuryprev-2022-044555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 03/26/2022] [Indexed: 11/05/2022]
Abstract
INTRODUCTION There is considerable uncertainty in estimates of traffic deaths in many sub-Saharan African countries, with the Global Burden of Disease (GBD) and the Global Status Report on Road Safety (GSRRS) reporting widely differing estimates. As a case study, we reviewed and compared estimates for Tanzania. METHODS We estimated the incidence of traffic deaths and vehicle ownership in Tanzania from nationally representative surveys. We compared findings with GBD and GSRRS estimates. RESULTS Traffic death estimates based on the 2012 census (9382 deaths; 95% CI: 7565 to 11 199) and the 2011-2014 Sample Vital Registration with Verbal Autopsy (8778; 95% CI: 7631 to 9925) were consistent with each other and were about halfway between GBD (5 608; 95% UI: 4506 to 7014) and WHO (16 252; 95% CI: 13 130 to 19 374) estimates and more than twice official statistics (3885 deaths in 2013). Surveys and vehicle registrations data show that motorcycles have increased rapidly since 2007 and now comprise 66% of vehicles. However, these trends are not reflected in GBD estimates of motorcycles in the country, likely resulting in an underestimation of motorcyclist deaths. CONCLUSION Reducing discrepancies between GBD and GSRRS estimates and demonstrating consistency with local epidemiological data will increase the legitimacy of such estimates among national stakeholders. GBD, which is the only project that models the road-user distribution of traffic deaths in all countries, likely severely underestimates motorcycle deaths in countries where there has been a recent increase in motorcycles. Addressing police under-reporting and strengthening surveillance capacity in Tanzania will allow a better understanding of the road safety problem and better targeting of interventions.
Collapse
Affiliation(s)
| | - Sudeshna Mitra
- Global Road Safety Facility, World Bank, Washington, DC, USA
| | - Kazuyuki Neki
- Global Road Safety Facility, World Bank, Washington, DC, USA
| | - Hialy Gutierrez
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | | | - Mercer Winer
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Jaeda Roberts
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Theo Vos
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA
| | - Erin Hamilton
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA
| | - Mohsen Naghavi
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA
| | | | - Soames Job
- Global Road Safety Facility, World Bank, Washington, DC, USA
| | - Kavi Bhalla
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| |
Collapse
|
12
|
Vergote I, Fidalgo AP, Hamilton E, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson D, Alía EG, Scambia G, Henry S, Wimberger P, Miller D, Martínez J, Monk B, Shacham S, Mirza M, Makker V. VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
13
|
Gutierrez H, Mitra S, Neki K, Mbugua LW, Balasubramaniyan R, Winer M, Roberts J, Vos T, Hamilton E, Naghavi M, Harrison JE, Job RFS, Bhalla K. Comparing estimates of road traffic deaths and non-fatal road traffic injuries in Cambodia. Inj Prev 2022; 28:340-346. [PMID: 35149595 DOI: 10.1136/injuryprev-2021-044504] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 01/22/2022] [Indexed: 12/18/2022]
Abstract
INTRODUCTION Timely, accurate and detailed information about traffic injuries are essential for managing national road safety programmes. However, there is considerable under-reporting in official statistics of many low and middle-income countries (LMICs) and large discrepancies between estimates from the Global Burden of Disease (GBD) study and WHO's Global Health Estimates (GHE). We compared all sources of epidemiological information on traffic injuries in Cambodia to guide efforts to improve traffic injury statistics. METHODS We estimated the incidence of traffic deaths and injuries and household ownership of motor vehicles in Cambodia from nationally representative surveys and censuses. We compared findings with GDB and GHE estimates. RESULTS We identified seven sources for estimating traffic deaths and three for non-fatal injuries that are not included as data sources in GBD and GHE models. These sources and models suggest a fairly consistent estimate of approximately 3100 deaths annually, about 50% higher than official statistics, likely because most hospital deaths are not recorded. Surveys strongly suggest that the vehicle fleet is dominated by motorcycles, which is not consistent with GBD estimates that suggest similar numbers of motorcyclist and vehicle occupant deaths. Estimates of non-fatal injuries from health surveys were about 7.5 times official statistics and 1.5 times GBD estimates. CONCLUSION Including local epidemiological data sources from LMICs can help reduce uncertainty in estimates from global statistical models and build trust in estimates among local stakeholders. Such analysis should be used as a benchmark to assess and strengthen the completeness of reporting of the national surveillance system.
Collapse
Affiliation(s)
- Hialy Gutierrez
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Sudeshna Mitra
- Global Road Safety Facility, World Bank, Washington, DC, USA
| | - Kazuyuki Neki
- Global Road Safety Facility, World Bank, Washington, DC, USA
| | | | | | - Mercer Winer
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Jaeda Roberts
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Theo Vos
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA
| | - Erin Hamilton
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA
| | - Mohsen Naghavi
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA
| | - James E Harrison
- Research Center for Injury Studies, Flinders University, Bedford Park, South Australia, Australia
| | - R F Soames Job
- Global Road Safety Facility, World Bank, Washington, DC, USA
| | - Kavi Bhalla
- Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| |
Collapse
|
14
|
O'Shaughnessy J, Rastogi P, Harbeck N, Toi M, Hegg R, Sohn J, Guarneri V, Cortes J, Hamilton E, Wei R, Shahir A, San Antonio B, Nabinger S, Tolaney S, Martin M, Johnston S. VP8-2021: Adjuvant abemaciclib combined with endocrine therapy (ET): Updated results from monarchE. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.09.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
15
|
Mitra S, Neki K, Mbugua LW, Gutierrez H, Bakdash L, Winer M, Balasubramaniyan R, Roberts J, Vos T, Hamilton E, Naghavi M, Harrison JE, Job RFS, Bhalla K. Availability of population-level data sources for tracking the incidence of deaths and injuries from road traffic crashes in low-income and middle-income countries. BMJ Glob Health 2021; 6:bmjgh-2021-007296. [PMID: 34782357 PMCID: PMC8593700 DOI: 10.1136/bmjgh-2021-007296] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Accepted: 10/17/2021] [Indexed: 11/05/2022] Open
Abstract
Introduction Tracking progress towards Sustainable Development Goal (SDG) 3·6 of reducing traffic deaths and serious injuries poses a measurement challenge in most low-income and middle-income countries (LMICs) due to large discrepancies between reported official statistics and estimates from global health measurement studies. We assess the extent to which national population censuses and health surveys can fill the information gaps. Methods We reviewed questionnaires for nationally representative surveys and censuses conducted since 2000 in LMICs. We identified sources that provide estimates of household ownership of vehicles, incidence of traffic deaths and non-fatal injuries, and prevalence of disability. Results We identified 802 data sources from 132 LMICs. Sub-Saharan African countries accounted for 43% of all measurements. The number of measurements since 2000 was high, with 97% of the current global LMIC population having at least one measurement for vehicle ownership, 77% for deaths, 90% for non-fatal injuries and 50% for disability due to traffic injuries. Recent data (since 2010) on traffic injuries were available from far fewer countries (deaths: 21 countries; non-fatal injuries: 62 and disability: 12). However, there were many more countries with recent data on less-specific questions about unintentional or all injuries (deaths: 41 countries, non-fatal: 87, disability: 32). Conclusion Traffic injuries are substantially underreported in official statistics of most LMICs. National surveys and censuses provide a viable alternative information source, but despite a large increase in their use to monitor SDGs, traffic injury measurements have not increased. We show that relatively small modifications and additions to questions in forthcoming surveys can provide countries with a way to benchmark their existing surveillance systems and result in a substantial increase in data for tracking road traffic injuries globally.
Collapse
Affiliation(s)
- Sudeshna Mitra
- World Bank Global Road Safety Facility, Washington, District of Columbia, USA
| | - Kazuyuki Neki
- World Bank Global Road Safety Facility, Washington, District of Columbia, USA
| | - Leah Watetu Mbugua
- World Bank Global Road Safety Facility, Washington, District of Columbia, USA
| | - Hialy Gutierrez
- Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Leen Bakdash
- Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Mercer Winer
- Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | | | - Jaeda Roberts
- Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| | - Theo Vos
- Institute for Health Metrics and Evaluation, Seattle, Washington, USA
| | - Erin Hamilton
- Institute for Health Metrics and Evaluation, Seattle, Washington, USA
| | - Mohsen Naghavi
- Institute for Health Metrics and Evaluation, Seattle, Washington, USA
| | - James E Harrison
- Research Center for Injury Studies, Flinders University, Adelaide, South Australia, Australia
| | - R F Soames Job
- World Bank Global Road Safety Facility, Washington, District of Columbia, USA
| | - Kavi Bhalla
- Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA
| |
Collapse
|
16
|
Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, Sohn J, Guarneri V, Cortés J, Hamilton E, André V, Wei R, Barriga S, Sherwood S, Forrester T, Munoz M, Shahir A, San Antonio B, Nabinger SC, Toi M, Johnston SRD, O'Shaughnessy J. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021; 32:1571-1581. [PMID: 34656740 DOI: 10.1016/j.annonc.2021.09.015] [Citation(s) in RCA: 185] [Impact Index Per Article: 61.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 09/22/2021] [Accepted: 09/27/2021] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of the prespecified primary outcome analysis and an additional follow-up analysis. PATIENTS AND METHODS This global, phase III, open-label trial randomized (1 : 1) 5637 patients to adjuvant ET for ≥5 years ± abemaciclib for 2 years. Cohort 1 enrolled patients with ≥4 positive axillary lymph nodes (ALNs), or 1-3 positive ALNs and either grade 3 disease or tumor ≥5 cm. Cohort 2 enrolled patients with 1-3 positive ALNs and centrally determined high Ki-67 index (≥20%). The primary endpoint was IDFS in the intent-to-treat population (cohorts 1 and 2). Secondary endpoints were IDFS in patients with high Ki-67, DRFS, overall survival, and safety. RESULTS At the primary outcome analysis, with 19 months median follow-up time, abemaciclib + ET resulted in a 29% reduction in the risk of developing an IDFS event [hazard ratio (HR) = 0.71, 95% confidence interval (CI) 0.58-0.87; nominal P = 0.0009]. At the additional follow-up analysis, with 27 months median follow-up and 90% of patients off treatment, IDFS (HR = 0.70, 95% CI 0.59-0.82; nominal P < 0.0001) and DRFS (HR = 0.69, 95% CI 0.57-0.83; nominal P < 0.0001) benefit was maintained. The absolute improvements in 3-year IDFS and DRFS rates were 5.4% and 4.2%, respectively. Whereas Ki-67 index was prognostic, abemaciclib benefit was consistent regardless of Ki-67 index. Safety data were consistent with the known abemaciclib risk profile. CONCLUSION Abemaciclib + ET significantly improved IDFS in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic, but abemaciclib benefit was observed regardless of Ki-67 index. Overall, the robust treatment benefit of abemaciclib extended beyond the 2-year treatment period.
Collapse
Affiliation(s)
- N Harbeck
- Breast Center, Department of OB & GYN and CCC Munich, LMU University Hospital, Munich, Germany.
| | - P Rastogi
- University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, USA
| | - M Martin
- Hospital General Universitario Gregorio Marañon, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain
| | | | - Z M Shao
- Fudan University Shanghai Cancer Center, Shanghai, China
| | - P A Fasching
- University Hospital Erlangen, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - C S Huang
- National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
| | - G G Jaliffe
- Grupo Medico Camino S.C., Mexico City, Mexico
| | - A Tryakin
- N.N.Blokhin Russian Cancer Research Center, Moscow, Russia
| | | | - H S Rugo
- Department of Medicine (Hematology/Oncology), University of California San Francisco, San Francisco, USA
| | - E Senkus
- Department of Oncology & Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
| | - L Testa
- Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, Brazil
| | | | - K Tamura
- National Cancer Center Hospital, Tokyo, Japan
| | - L Del Mastro
- IRCSS Ospedale Policlinico San Martino, UO Breast Unit, Genoa, Italy; Università di Genova, Department of Internal Medicine and Medical Specialties (DIM), Genoa, Italy
| | - G G Steger
- Medical University of Vienna, Vienna, Austria
| | - H Kreipe
- Medizinische Hochschule Hannover, Hannover, Germany
| | - R Hegg
- Clin. Pesq. e Centro São Paulo, São Paulo, Brazil
| | - J Sohn
- Yonsei Cancer Center, Seoul, Korea
| | - V Guarneri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy; Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - J Cortés
- International Breast Cancer Center (IBCC), Madrid & Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain
| | - E Hamilton
- Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA
| | - V André
- Eli Lilly and Company, Indianapolis, USA
| | - R Wei
- Eli Lilly and Company, Indianapolis, USA
| | - S Barriga
- Eli Lilly and Company, Indianapolis, USA
| | - S Sherwood
- Eli Lilly and Company, Indianapolis, USA
| | | | - M Munoz
- Eli Lilly and Company, Indianapolis, USA
| | - A Shahir
- Eli Lilly and Company, Indianapolis, USA
| | | | | | - M Toi
- Kyoto University Hospital, Kyoto, Japan
| | | | - J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA
| | | |
Collapse
|
17
|
Hamilton E, Schiavon G, Grinsted L, De Bruin E, Catanese M, Rugo H. 338TiP CAPItello-292: A phase 1b/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+/HER2− advanced breast cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.621] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
18
|
Klempner S, Beeram M, Sabanathan D, Chan A, Hamilton E, Loi S, Oh DY, Emens L, Patnaik A, Kim J, Park Y, Odegard V, Hamke S, Jang G, Jacquemont C, Hunder N, Piha-Paul S. 209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.491] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
19
|
O'Shaughnessy J, Brufsky A, Rugo H, Tolaney S, Diab S, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz S, Kalinsky K, Bardia A, Henry S, Mayer I, Hong Q, Phan S, Cortés J. 258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
20
|
Tripathy D, Ukrainskyj S, Yang Z, Kania M, Schelman W, Hamilton E. 337TiP An open-label, phase Ib/II study to evaluate the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced triple-negative breast cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
21
|
Miller K, Emens L, Tolaney S, Hurvitz S, Hamilton E, Paton V, Hannah A, Boni V. 127TiP Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
22
|
Bardia A, Juric D, Shimizu T, Tolcher A, Karim R, Spira A, Mukohara T, Lisberg A, Kogawa T, Krop I, Papadopoulos K, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F. LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.213] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
23
|
Spring L, Han H, Hamilton E, Irie H, Santa-Maria C, Reeves J, Pan P, Shan M, Tang Y, Graham J, Hazard S, Ellisen L, Isakoff S. Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer. Breast 2021. [DOI: 10.1016/s0960-9776(21)00183-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
24
|
Johnston S, Harbeck N, Hegg R, Toi M, Martin M, Shao Z, Campone M, Hamilton E, Sohn J, Guarneri V, Cortes J, Neven P, Boyle F, Smith I, Frenzel M, Headley D, Wei R, Cox J, O'Shaughnessy J, Rastogi P. 2MO Abemaciclib in high risk early breast cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
25
|
Papadopoulos K, Sharma M, Hamilton E, Richardson D, Bashir B, Hodgson G, Ke N, Kang-Fortner Q, Zhou L, Zamboni W, Jolin H, Madigan C, Kelly M, Roth D. Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)31211-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
26
|
Arend R, Castro C, Matulonis U, Hamilton E, Gunderson C, Lybarger K, Goodman H, Duska L, Mahdi H, ElNaggar A, Naik G, Kagey M, Barroilhet L, Bradley W, Sachdev J, O'Malley D, Sirard C, Birrer M. Dkn-01 treated patients with recurrent epithelial endometrial (EEC) or ovarian (EOC) cancers which harbor Wnt activating mutations have longer progression-free survival and improved clinical benefit. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.06.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
27
|
Hardesty M, Krivak T, Wright G, Hamilton E, Fleming E, Gupta D, Keeton E, Chen J, Clements A, Gray H, Konecny G, Moore R, Richardson D. Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.06.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Richardson D, Hamilton E, Tolcher A, Burns T, Edenfield W, Papadopoulos K, Matulonis U, Huebner D, Mosher R, Jarlenski D, Pennock G, Cyr M, Ulahannan S, Moore K. A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.06.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
29
|
Concin N, Gonzalez Martin A, Vergote I, Pignata S, Harter P, Patel M, Gunderson C, Wride K, Lepley D, Dusek R, Go J, Hurley S, Cameron T, Hamilton E. 885TiP LIO-1: A phase II study of lucitanib + nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2091] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
30
|
Curigliano G, Murthy R, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz S, Cameron D, Borges V, Bedard P, Oliveira M, Jakobsen E, Bachelot T, Shachar S, Mueller V, Carey L, Loibl S, Feng W, Walker L, Winer E. 137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
31
|
Valenta JM, Wu C, Modrow K, Hamilton E, Osburn WN. Investigation of the Fatty Acid Profile of the M. rhomboideus Derived from Bos indicus Cattle. Meat and Muscle Biology 2019. [DOI: 10.22175/mmb.10833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
ObjectivesResearch has shown the m. Rhomboideus (Rho) from purebred Bos indicus (BI) to be unique in its proximate chemical composition, indicated by increased lipid deposition. Thus, potential for the depostion of mono- (MUFA) and poly- unsaturated (PUFA) fatty acids exists. The objective of this study was to assess the fatty acid composition of the intramuscular (IMF) and subcutaneous (SQF) depots in the Rho from BI crossed cattle.Materials and MethodsThree replications of 4 USDA Choice (Ch) and 4 USDA Select (Se) Rho muscles were selected from the right half of split carcasses (N = 24). Selection parameters were > 7.62-cm hump height, > 7.62-cm width, > 25.4-cm length, weight range: 2–4-kg. Muscles were removed from carcasses and vacuum packaged. After a 14-d aging period, Rho muscles were fabricated, 2.54-cm serially cut steaks (anterior to posterior), trimmed to 0.254-mm fat thickness. Steaks were assigned identification tags and designated for analysis. Rho steaks were used for proximate composition (n = 2), trained sensory analysis (n = 2), Warner-Bratzler shear force (WBS, n = 1), collagen content (n = 1), and fatty acid composition of IMF and SQF (n = 1). Steaks for trained sensory analysis were also used for color measurements and cook yield. Data were analyzed using a 2-sample t test. Sensory data were analyzed using a linear fit model with order as a random effect. All data analyzed using JMP v14.0.0. A predetermined significance level of P < 0.05 was used.ResultsTotal MUFA, PUFA and saturated fatty acid (SFA) percentages of IMF were not significant (P > 0.05) between Ch Rho muscles (43, 7.2, 47.1%, 0.89, respectively) and Se Rho muscles (43.0, 6.3, 50.7%, 0.86, respectively). Mean averages across both quality grades for total MUFA, PUFA, SFA, and MUFA:SFA (42.2, 6.8, 48.9%, 0.87, respectively) in Rho IMF were similar to reported FAC averages of Bos taurus (BT) longissimus dorsi IMF (47.8, 4.4, 47.8%, 1.0, respectively).Total MUFA percentage (49.1 vs. 45.4%) and MUFA:SFA ratio (1.1 vs. 0.9) were significantly higher (P < 0.001) in Ch SQF compared to Se SQF. However, total PUFA percentage (4.3 vs. 3.7%) and SFA (50.3 vs. 47.0%) were significantly higher (P < 0.02) in Se SQF compared to Ch SQF. Mean averages across both quality grade for total MUFA, PUFA, SFA, and MUFA:SFA (47.4, 4, 48.6%, 0.99, respectively) in SQF were similar to reported fatty acid averages of BT brisket SQF (56.8, 3, and 35.9%; 1.47, respectively).Protein content (19.4 vs. 18.6%) was higher (P < 0.02) for Ch than Se Rho muscles. L* value (50.2 vs. 47.9) was larger (P < 0.05) for Se. Ch Rho muscles contained greater amounts (P < 0.001) of total, insoluble, and soluble collagen (21.8, 21.5, 0.3 mg/g, respectively) compared to Se Rho muscles (13.8, 13.7, 0.1 mg/g, respectively). Ch Rho muscles were more tender (P < 0.001) as determined by WBS values (2.6 vs. 3.1 kg). Trained sensory analysis, pH, fat, moisture, a* and b* color values between quality grades were not different (P > 0.05).ConclusionDifferences were not seen for fatty acid composition between Ch and Se Rho IMF fat. However, higher percentages of total PUFA were found in both Ch and Se Rho IMF compared to reported longissimus dorsi IMF. Additionally, Ch Rho SQF contained higher percentages of total MUFA. However, Se Rho SQF contained higher percentages of total PUFA and SFA. Higher percentages of SFA were found in both Ch and Se SQF compared to reported brisket SQF SFA values.
Collapse
Affiliation(s)
| | - C. Wu
- Texas A&M University Animal Science
| | | | | | | |
Collapse
|
32
|
Wu C, Valenta J, Hamilton E, Modrow K, Osburn WN. The Optimization of the Concentrations of Sodium Lactate (Nal), Sodium Erythorbate (Nae), and Sodium Bicarbonate (Nab) Applied to Beef Trimmings for Ground Beef Production. Meat and Muscle Biology 2019. [DOI: 10.22175/mmb.10728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
ObjectivesThe objective of the study was to identify optimal concentrations of NaL, NaE and NaB applied to beef trimmings to assess their impact on quality of ground beef patties.Materials and MethodsBeef trimmings (∼50kg) were fabricated from beef forequarters (N = 5) 14 d postmortem, combined and aerobically stored (5°C) for an additional 6 d to simulate the collection, storage, transportation and receipt of a combo of beef trimmings. A 23 central composite response surface design (RSM) was used to generate 15 treatment combinations containing NaL (0.1–1.5 M), NaE (0.1–0.6 M), and NaB (0.1–1.5 M) with water used as a control. After aerobic storage, the beef trimmings (∼20% fat) were coarse ground (12 mm) and the treatment/control solution applied to the coarse ground trimmings (∼454 g) at 2% (w/w). The trimmings were reground (3 mm) and 120 g of treated sample was placed into a Petri dish and overwrapped with oxygen permeable film (OTR: 21,700 cc/m2/24h at 25°C) to form patties. The patties (2 per treatment/control) were stored under simulated retail conditions: 5°C, cool white fluorescent light (200–300 lux) and analyzed at Day 0, 3, 6, and 9 of storage to assess the effectiveness of each treatment in preventing further quality deterioration. Objective color (L*, a*, b*), 2-thiobarbituric acid (TBA) determinations, GC–MS for off-odor assessment and aerobic plate counts (APC) were conducted. The least squares means of results were generated by one-way ANOVA and Tukey HSD to identify significant differences (P < 0.05) between treatment and control patties. For RSM and multivariate RSM analyses, the data was used to generate total quadratic polynomial linear regression models and contour plots to determine the optimum ingredient concentrations for the solution.ResultsThe a* values of treated indicated a redder surface color from Day 0 to Day 9 (P < 0.05). No difference was observed for treated and control patties for TBA and hexanal counts on Day 0. The TBA values for all treatments reduced lipid oxidation compared to the control on Day 3, 6, and 9 (0.47– 0.58 vs. 0.71, 0.51– 0.58 vs. 0.74 and 0.45– 0.62 vs. 0.74, respectively; P < 0.05). No differences were observed for treated and control patties for APC from Day 0 to Day 6, except on Day 9 (8.10 vs. 8.21 Log10 CFU/g; P < 0.05). Based on these results, a* and TBA values were used to conduct RSM analyses for Day 3 and 6. Day 9 was excluded due to a significant lack of fit. The predicted value of hexanal was 0 for all treatments. The prediction of TBA values found optimum ingredient concentrations on Day 6: NaL (0.74 M), NaE (0.35 M) and NaB (1.00 M) (R2 = 0.77, respectively; P < 0.05). The prediction of a* values on Day 3 and 6 did not identify optimum ingredient concentrations for any treatment solution (R = 0.94 and 0.78, respectively; P < 0.05). Multivariate RSM was conducted to overlap the contour plots of a* and TBA values at Day 3 and 6 to better approximate the optimal ingredient concentrations for a* values. The proximal optimum concentration ranges of solutions based on the analysis were 0.3- 0.5 M NaL, 0.35 M NaE and 1M NaB with predicted a* values > 11 and TBA values < 0.52.ConclusionResults of this study suggest that a combination of NaB, NaE, and NaL can be applied to improve color stability, reduce lipid oxidation, and control off-odor of ground beef patties.
Collapse
Affiliation(s)
- C. Wu
- Texas A&M University Animal Science
| | | | | | | | | |
Collapse
|
33
|
Oh DY, Hamilton E, Hanna D, Beeram M, Lee KW, Kang YK, Chaves J, Lee JY, Goodwin R, Vaklavas C, Rha SY, Elimova E, Mayordomo J, Ferrario C, Cobleigh M, Fortenberry A, Rowse G, Gray T, Lai R, Meric Bernstam F. Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz420] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Italiano A, Infante JR, Shapiro GI, Moore KN, LoRusso PM, Hamilton E, Cousin S, Toulmonde M, Postel-Vinay S, Tolaney S, Blackwood EM, Mahrus S, Peale FV, Lu X, Moein A, Epler J, DuPree K, Tagen M, Murray ER, Schutzman JL, Lauchle JO, Hollebecque A, Soria JC. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. Ann Oncol 2019; 29:1304-1311. [PMID: 29788155 DOI: 10.1093/annonc/mdy076] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Checkpoint kinase 1 (Chk1) inhibition following chemotherapy-elicited DNA damage overrides cell cycle arrest and induces mitotic catastrophe and cell death. GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor that results in tumor shrinkage and growth delay in xenograft models. We evaluated the safety, tolerability, and pharmacokinetic properties of GDC-0575 alone and in combination with gemcitabine. Antitumor activity and Chk1 pathway modulation were assessed. PATIENTS AND METHODS In this phase I open-label study, in the dose escalation stage, patients were enrolled in a GDC-0575 monotherapy Arm (1) or GDC-0575 combination with gemcitabine Arm (2) to determine the maximum tolerated dose. Patients in arm 2 received either i.v. gemcitabine 1000 mg/m2 (arm 2a) or 500 mg/m2 (arm 2b), followed by GDC-0575 (45 or 80 mg, respectively, as RP2D). Stage II enrolled disease-specific cohorts. RESULTS Of 102 patients treated, 70% were female, the median age was 59 years (range 27-85), and 47% were Eastern Cooperative Oncology Group PS 0. The most common tumor type was breast (37%). The most frequent adverse events (all grades) related to GDC-0575 and/or gemcitabine were neutropenia (68%), anemia (48%), nausea (43%), fatigue (42%), and thrombocytopenia (35%). Maximum concentrations of GDC-0575 were achieved within 2 hours of dosing, and half-life was ∼23 hours. No pharmacokinetic drug-drug interaction was observed between GDC-0575 and gemcitabine. Among patients treated with GDC-0575 and gemcitabine, there were four confirmed partial responses, three occurring in patients with tumors harboring TP53 mutation. Pharmacodynamic data were consistent with GDC-0575 inhibition of gemcitabine-induced expression of pCDK1/2. CONCLUSION GDC-0575 can be safely administered as a monotherapy and in combination with gemcitabine; however, overall tolerability with gemcitabine was modest. Hematological toxicities were frequent but manageable. Preliminary antitumor activity was observed but limited to a small number of patients with a variety of refractory solid tumors treated with GDC-0575 and gemcitabine. CLINICAL TRIAL NUMBER NCT01564251.
Collapse
Affiliation(s)
- A Italiano
- Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France.
| | - J R Infante
- Sarah Cannon Research Institute, Nashville; Tennessee Oncology, Nashville
| | - G I Shapiro
- Early Drug Development Center; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - K N Moore
- Stevenson Oklahoma Cancer Center, Oklahoma City; University of Oklahoma, Oklahoma City
| | - P M LoRusso
- Smilow Cancer Center, New Haven; Yale University, New Haven, USA
| | - E Hamilton
- Sarah Cannon Research Institute, Nashville; Tennessee Oncology, Nashville
| | - S Cousin
- Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France
| | - M Toulmonde
- Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France
| | - S Postel-Vinay
- Départemement d'Innovation Thérapeutique et des Essais Précoces (DITEP), Villejuif; Gustave Roussy, Villejuif; Université Paris Saclay, Villejuif; INSERM, U981, Villejuif, France
| | - S Tolaney
- Early Drug Development Center; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | | | - S Mahrus
- Genentech, Inc., South San Francisco, USA
| | - F V Peale
- Genentech, Inc., South San Francisco, USA
| | - X Lu
- Genentech, Inc., South San Francisco, USA
| | - A Moein
- Genentech, Inc., South San Francisco, USA
| | - J Epler
- Genentech, Inc., South San Francisco, USA
| | - K DuPree
- Genentech, Inc., South San Francisco, USA
| | - M Tagen
- Genentech, Inc., South San Francisco, USA
| | - E R Murray
- Genentech, Inc., South San Francisco, USA
| | | | | | - A Hollebecque
- Départemement d'Innovation Thérapeutique et des Essais Précoces (DITEP), Villejuif; Gustave Roussy, Villejuif; Université Paris Saclay, Villejuif
| | | |
Collapse
|
35
|
Hamilton E, Wang J, Li D, Dasari N, Paulson S, Cohn A, Sauter N, Kania M, Kauh J, Falchook G. Safety and tolerability of surufatinib in western patients with solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz256.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
36
|
Spring L, Shan M, Liu M, Hamilton E, Santa-Maria C, Irie H, Isakoff S, Reeves J, Ellisen L, Liem A, Naraine AM, Nangia J, Page D, Pan P, Sun K, Graham J, Han H. Clinical confirmation of higher exposure to niraparib in tumour vs plasma in patients with breast cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
Hamilton E, Vidula N, Ma C, LoRusso P, Bagley R, Yu Z, Annett M, Weitzman A, Conlan M, Weise A. Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Meric-Bernstam F, Hanna D, Beeram M, Lee KW, Kang YK, Chaves J, Lee J, Goodwin R, Vaklavas C, Oh DY, Rha S, Elimova E, Mayordomo J, Ferrario C, Cobleigh M, Fortenberry A, Rowse G, Gray T, Lai R, Hamilton E. Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
39
|
Arend R, Castro C, Matulonis U, Hamilton E, Gunderson C, Lybarger K, Kagey M, Sirard C, Birrer M. Safety and efficacy of a DKK1 inhibitor (DKN-01) as monotherapy or in combination with paclitaxel in patients with Wnt activated recurrent gynecologic malignancies. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.080] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Patler C, Hamilton E, Meagher K, Savinar R. Uncertainty About DACA May Undermine Its Positive Impact On Health For Recipients And Their Children. Health Aff (Millwood) 2019; 38:738-745. [DOI: 10.1377/hlthaff.2018.05495] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Caitlin Patler
- Caitlin Patler is an assistant professor of sociology at the University of California Davis
| | - Erin Hamilton
- Erin Hamilton is an associate professor of sociology at the University of California Davis
| | - Kelsey Meagher
- Kelsey Meagher is a PhD candidate in sociology at the University of California Davis
| | - Robin Savinar
- Robin Savinar is a postdoctoral fellow in sociology at the University of California Davis
| |
Collapse
|
41
|
Han H, Hamilton E, Irie H, Isakoff S, Jelovac D, Liem A, Liu MC, Milillo A, Nangia J, Page D, Reeves J, Santa-Maria C, Duncan M, Graham JR, Chen J, Dezube BJ, Spring L. Abstract OT3-03-01: Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot3-03-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant chemotherapy is administered to patients with operable breast cancer to downstage the tumor to allow for less extensive surgery and to provide prognostic information about drug efficacy and risk of disease recurrence. Patients who achieve a pathological complete response (pCR) following neoadjuvant treatment have a more favorable outcome than patients with residual invasive disease. Single-agent poly(ADP-ribose) polymerase (PARP) inhibitors have clinical efficacy in BRCA-mutated breast cancer. Niraparib, a potent and selective PARP1/2 inhibitor, is approved for maintenance treatment of patients with recurrent ovarian cancer and has demonstrated strong antitumor activity in in vivo studies with BRCA1-mutant breast cancer. The objective of this study is to evaluate the antitumor activity of single-agent niraparib in the neoadjuvant treatment of patients with localized, human epidermal growth factor receptor 2 (HER2)-negative, BRCAmut breast cancer.
Trial Design: This is an open-label, single-arm pilot study with a target enrollment of 20 evaluable patients. Eligible patients are those ≥18 years old with histologically-confirmed HER2-negative localized breast cancer and either a BRCA1 or BRCA2 mutation (germline or somatic) and no prior anti-cancer therapies for the current malignancy. Patients will receive 200 mg of oral niraparib once daily for 2 months, after which they may either proceed directly to surgery or receive chemotherapy at the discretion of the physician. The primary endpoint is tumor response rate based on the change in tumor volume as measured by breast MRI after 2 months of treatment with niraparib; a response is defined as ≥30% reduction of tumor volume from baseline. Secondary endpoints include pCR rate, tumor response rate based on the change in tumor volume as measured by breast ultrasound, and safety and tolerability. Data will be summarized in a descriptive nature by frequency distributions (number and percentage of patients) for categorical variables and by the mean, median, and standard deviation for continuous variables. Tumor response rate will be tabulated together with its 95% binomial exact confidence interval.
Funding: TESARO, Inc., Waltham, MA, USA sponsored the study.
Citation Format: Han H, Hamilton E, Irie H, Isakoff S, Jelovac D, Liem A, Liu MC, Milillo A, Nangia J, Page D, Reeves J, Santa-Maria C, Duncan M, Graham JR, Chen J, Dezube BJ, Spring L. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT3-03-01.
Collapse
Affiliation(s)
- H Han
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - E Hamilton
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - H Irie
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - S Isakoff
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - D Jelovac
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - A Liem
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - MC Liu
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - A Milillo
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - J Nangia
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - D Page
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - J Reeves
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - C Santa-Maria
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - M Duncan
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - JR Graham
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - J Chen
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - BJ Dezube
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| | - L Spring
- Moffitt Cancer Center-McKinley Outpatient Clinic, Tampa, FL; Tennessee Oncology, Nashville, TN; Icahn School of Medicine at Mount Sinai, New York, NY; Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Pacific Shores Medical Group, Long Beach, CA; Mayo Clinic Rochester, Rochester, MN; Memorial Health Care System, Hollywood, FL; Baylor College of Medicine, Houston, TX; Providence Portland Medical Center, Portland, OR; Florida Cancer Specialists-South, Fort Myers, FL; TESARO, Inc., Waltham, MA
| |
Collapse
|
42
|
Hamilton E, Cortes J, Dieras V, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, Jerusalem G, Hegg R, Lu Y, Bear MM, Johnston EL, Martin M. Abstract PD1-11: nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd1-11] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Abemaciclib is a selective CDK4 & 6 inhibitor approved on a continuous dosing schedule for HR+, HER2- advanced breast cancer (ABC) as monotherapy (MONARCH 1) and in combination with endocrine therapy (ET). A previous Phase 1b (NCT01394016) cohort of HR+ ABC patients (pts) demonstrated efficacy of abemaciclib monotherapy (150mg and 200mg Q12H starting dose); given the small sample size and nonrandomized design the impact of the starting dose was unclear. nextMONARCH 1 (NCT02747004) evaluated abemaciclib in 2 monotherapy arms, in a randomized setting. Abemaciclib has been associated with dose-dependent early onset diarrhea that is well managed with antidiarrheal therapy. nextMONARCH 1 also explored the 200mg Q12H abemaciclib dose in combination with prophylactic loperamide to reduce incidence/severity of diarrhea and dose adjustments. A third arm evaluated abemaciclib + tamoxifen as a strategy to overcome endocrine resistance.
Methods
nextMONARCH 1 is a multicenter, randomized, open-label, Phase 2 study of abemaciclib or abemaciclib + tamoxifen in women with HR+, HER2- ABC who have progressed on or after prior ET and previously received chemotherapy. Pts were stratified by presence of liver metastases and prior use of tamoxifen in the advanced setting. Randomization was 1:1:1 to abemaciclib 150mg Q12H + daily tamoxifen 20mg (Arm A) or abemaciclib 150mg Q12H (Arm B); or abemaciclib 200mg Q12H + prophylactic loperamide (Arm C). Key eligibilities were ≥2 chemotherapy regimens (1-2 administered in metastatic setting), measurable disease and no prior treatment with CDK4 & 6 inhibitors. Primary objective was progression free survival (PFS). Key secondary objectives included objective response rate (ORR), dclinical benefit rate (CBR), and safety. PFS analysis tested superiority of Arm A to C at ∼110 events across the 2 arms assuming a hazard ratio (HR) of 0.667 to achieve ∼80% power. Arm B would be considered non-inferior to Arm C if the observed PFS HR is <1.2.
Results
234 pts were randomized to Arms A (n=78), B (n=79) and C (n=77). 166 PFS events have been observed (A: 57; B: 54; C: 55). Median PFS was 9.1 months in Arm A, 6.5 in Arm B and 7.4 in Arm C (A vs C: HR=.815, 95% CI, .556-1.193, p=.293; B vs C: HR=1.045, 95% CI, .711-1.535 p=.811). Investigator-assessed ORR was 34.6%, 24.1% and 32.5% (confirmed ORR: 25.6%, 19.0%, 28.6%) and CBR was 61.5%, 49.4% and 51.9% in Arms A, B and C, respectively. Prophylactic loperamide reduced the incidence and severity of diarrhea (C: 62.3%, Gr 3: 7.8%) compared to MONARCH 1 (90.2%, Gr 3: 19.7%, Dickler et al. 2017) resulting in similar rates of diarrhea with 150mg abemaciclib without prophylaxis (A: 53.8%, Gr 3: 1.3%; B: 67.1%, Gr 3: 3.8%). The adverse event profile across arms was generally consistent with other breast studies of abemaciclib.
Conclusions
nextMONARCH 1 confirmed single-agent activity of abemaciclib in heavily pretreated pts with HR+, HER2- ABC. Efficacy of abemaciclib monotherapy at 150mg was similar to 200mg. Combining tamoxifen with abemaciclib did not demonstrate a statistically significant improvement in PFS compared to abemaciclib monotherapy. Addition of prophylactic loperamide to abemaciclib 200mg resulted in diarrhea similar to 150mg without prophylaxis.
Citation Format: Hamilton E, Cortes J, Dieras V, Ozyilkan O, Chen S-C, Petrakova K, Manikhas A, Jerusalem G, Hegg R, Lu Y, Bear MM, Johnston EL, Martin M. nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD1-11.
Collapse
Affiliation(s)
- E Hamilton
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - J Cortes
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - V Dieras
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - O Ozyilkan
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - S-C Chen
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - K Petrakova
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - A Manikhas
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - G Jerusalem
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - R Hegg
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - Y Lu
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - MM Bear
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - EL Johnston
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| | - M Martin
- Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville; Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Centre Eugene Marquis UNICANCER, Rennes Cedex, France; Baskent University, Adana, Turkey; Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan; Masarykuv Onkologický Ustav, Brno, Czech Republic; City Clinical Oncology Dispensary, St. Petersburg, Russian Federation; Centre Hospitalier Universitaire, Liege, Belgium; Hospital Pérola Byington/FMUSP, Centro de Referência da Saúde da Mulher, São Paulo, Brazil; Eli Lilly and Company, Indianapolis; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
| |
Collapse
|
43
|
Paplomata E, Borges V, Loi S, Abramson V, Hamilton E, Hurvitz S, Lin N, Walker L, Murthy RK. Abstract OT2-07-08: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-07-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Paplomata E, Borges V, Loi S, Abramson V, Hamilton E, Hurvitz S, Lin N, Walker L, Murthy RK. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-07-08.
Collapse
Affiliation(s)
- E Paplomata
- Emory Winship Cancer Institute, Atlanta, GA; University of Colorado Cancer Center, Aurora, CO; Peter MacCallum Cancer Centre, Victoria, Australia; Vanderbilt-Ingram Cancer Center, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; Seattle Genetics, Inc., Bothell, WA; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - V Borges
- Emory Winship Cancer Institute, Atlanta, GA; University of Colorado Cancer Center, Aurora, CO; Peter MacCallum Cancer Centre, Victoria, Australia; Vanderbilt-Ingram Cancer Center, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; Seattle Genetics, Inc., Bothell, WA; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Loi
- Emory Winship Cancer Institute, Atlanta, GA; University of Colorado Cancer Center, Aurora, CO; Peter MacCallum Cancer Centre, Victoria, Australia; Vanderbilt-Ingram Cancer Center, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; Seattle Genetics, Inc., Bothell, WA; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - V Abramson
- Emory Winship Cancer Institute, Atlanta, GA; University of Colorado Cancer Center, Aurora, CO; Peter MacCallum Cancer Centre, Victoria, Australia; Vanderbilt-Ingram Cancer Center, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; Seattle Genetics, Inc., Bothell, WA; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - E Hamilton
- Emory Winship Cancer Institute, Atlanta, GA; University of Colorado Cancer Center, Aurora, CO; Peter MacCallum Cancer Centre, Victoria, Australia; Vanderbilt-Ingram Cancer Center, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; Seattle Genetics, Inc., Bothell, WA; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - S Hurvitz
- Emory Winship Cancer Institute, Atlanta, GA; University of Colorado Cancer Center, Aurora, CO; Peter MacCallum Cancer Centre, Victoria, Australia; Vanderbilt-Ingram Cancer Center, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; Seattle Genetics, Inc., Bothell, WA; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - N Lin
- Emory Winship Cancer Institute, Atlanta, GA; University of Colorado Cancer Center, Aurora, CO; Peter MacCallum Cancer Centre, Victoria, Australia; Vanderbilt-Ingram Cancer Center, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; Seattle Genetics, Inc., Bothell, WA; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L Walker
- Emory Winship Cancer Institute, Atlanta, GA; University of Colorado Cancer Center, Aurora, CO; Peter MacCallum Cancer Centre, Victoria, Australia; Vanderbilt-Ingram Cancer Center, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; Seattle Genetics, Inc., Bothell, WA; The University of Texas MD Anderson Cancer Center, Houston, TX
| | - RK Murthy
- Emory Winship Cancer Institute, Atlanta, GA; University of Colorado Cancer Center, Aurora, CO; Peter MacCallum Cancer Centre, Victoria, Australia; Vanderbilt-Ingram Cancer Center, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Dana-Farber Cancer Institute, Boston, MA; Seattle Genetics, Inc., Bothell, WA; The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
44
|
Adams S, Hamilton E, Ott PA, Cho D, Kalinsky K, LoRusso P, Will M, Huels V, Benson B, Murias C, Arkenau HT. Abstract P6-18-31: PROCLAIM-CX-072: Monotherapy for advanced triple negative breast cancer with skin metastases in a phase 1-2 trial of the PD-L1 probody therapeutic CX-072. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Probody™ therapeutics are novel, fully recombinant antibody prodrugs designed to remain relatively inactive in healthy tissue and to be specifically activated by proteases in the tumor microenvironment. In this way, Probody therapeutics may broaden the therapeutic window for effective but potentially toxic anticancer agents. CX-072 is a Probody therapeutic directed against programmed death-ligand 1 (PD-L1) for the treatment of cancer patients. In a first-in-human, open-label, multicenter, dose-escalation, 3+3 design, phase 1-2 study, PROCLAIM-CX-072 (PRObody CLinical Assessment In Man) (NCT03013491), 22 patients were enrolled in the phase 1 dose escalation portion. Twenty patients were evaluable per RECIST v1.1. Three patients had confirmed partial response (15%), including a 39-year-old woman with stage IV triple negative breast cancer (TNBC) treated with 10 mg/kg CX-072 monotherapy whose disease had progressed on one previous line of chemotherapy for metastatic disease. Metastatic sites included extensive nodal disease and skin/chest wall lesions. The tumor was negative for PD-L1 expression, was microsatellite stable, and had a low tumor mutational burden (4 mutations/megabase). Positive results from the phase 1 study suggest that additional exploration of treatment with CX-072 monotherapy in the TNBC patient population is warranted.
Dose expansion trial design: The phase 2 dose expansion part of the PROCLAIM-CX-072 study will include enrollment of TNBC patients with skin metastases. Key inclusion criteria for patients in the TNBC cohort are as follows: naive to immunotherapy (PD-1/PD-L1 and CTLA-4 inhibitors), approved immune checkpoint inhibitor agents not available, histologically confirmed triple negative (estrogen receptor–, progesterone receptor–, and human epidermal growth factor receptor-2–negative cancer per ASCO-CAP guidelines), previously treated with 1 to 3 systemic chemotherapy regimens, and locally advanced and recurrent skin or subcutaneous metastases not suitable for surgical resection or radiotherapy. Patients will receive doses of 10 mg/kg CX-072 intravenously every 2 weeks. Efficacy will be evaluated using RECIST v1.1 and immune-related RECIST criteria. Safety and tolerability will be assessed based on the incidence and severity of adverse events (categorized by NCI CTCAE criteria, v4.03) and relationship to study drug. Other analyses will include pharmacokinetics, incidence of anti-drug antibodies against CX-072, exploratory analysis for immune response, and CX-072 activation in the tumor.
PROBODY is a trademark of CytomX Therapeutics, Inc.
Citation Format: Adams S, Hamilton E, Ott PA, Cho D, Kalinsky K, LoRusso P, Will M, Huels V, Benson B, Murias C, Arkenau H-T. PROCLAIM-CX-072: Monotherapy for advanced triple negative breast cancer with skin metastases in a phase 1-2 trial of the PD-L1 probody therapeutic CX-072 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-31.
Collapse
Affiliation(s)
- S Adams
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - E Hamilton
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - PA Ott
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - D Cho
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - K Kalinsky
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - P LoRusso
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - M Will
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - V Huels
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - B Benson
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - C Murias
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| | - H-T Arkenau
- Perlmutter Cancer Center, New York University School of Medicine, New York, NY; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Columbia University Medical Center, New York, NY; Yale University School of Medicine, Yale Cancer Center, New Haven, CT; CytomX Therapeutics, Inc., South San Francisco, CA; Sarah Cannon Research Institute UK Ltd, London, United Kingdom
| |
Collapse
|
45
|
Donato KM, Caron L, Hamilton E. Migration and Mental Health in Mexico: Domestic Migrants, Return U.S. Migrants, and Non-Migrants. Front Psychiatry 2019; 10:970. [PMID: 32116812 PMCID: PMC7008711 DOI: 10.3389/fpsyt.2019.00970] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Accepted: 12/09/2019] [Indexed: 11/26/2022] Open
Abstract
In this paper, we use survey data from the Mexican Retrospective Demographic Survey (Encuesta Demográfica Retrospectiva) and National Survey of Households (Encuesta Nacional de Hogares) collected in 2017 to examine self-reports of depression, anxiety, chronic fatigue, and pain among domestic migrants, returned U.S. migrants, and non-migrants. Although self-reports do not always correspond to clinical diagnoses, they offer some insight into mental health, especially for those without a diagnosis because of limited access to services or stigma. Regression results reveal that domestic migrants, e.g., those who moved within Mexico, reported more anxiety, chronic fatigue, and pain, but risks for U.S. migrants were comparable to non-migrants, controlling for other characteristics. Findings from the decomposition analysis helps explain these findings. While domestic migrant vs. non-migrant differences result both from different migrant demographic attributes, such as age and gender, and differences in the effects of these characteristics between the groups, U.S. migrant vs. non-migrant differences in anxiety and pain emerge only after allowing for the relationship between each observed characteristic and the mental health outcome to vary. Thus, compared to domestic migrants, U.S. migrants are selected on characteristics associated with good mental health-they are positively selected-but those characteristics are not protective for them.
Collapse
Affiliation(s)
- Katharine M Donato
- Walsh School of Foreign Service, Georgetown University, Washington, DC, United States
| | - Laura Caron
- Walsh School of Foreign Service, Georgetown University, Washington, DC, United States
| | - Erin Hamilton
- University of California, Davis, Davis, CA, United States
| |
Collapse
|
46
|
Valenta JM, Wu C, Modrow K, Hamilton E, Osburn WN. Investigation of the Fatty Acid Profile of the M. rhomboideus Derived from Bos indicus Cattle. Meat and Muscle Biology 2019. [DOI: 10.22175/mmb2019.0170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
47
|
Wu C, Valenta J, Hamilton E, Modrow K, Osburn WN. The Optimization of the Concentrations of Sodium Lactate (Nal), Sodium Erythorbate (Nae), and Sodium Bicarbonate (Nab) Applied to Beef Trimmings for Ground Beef Production. Meat and Muscle Biology 2019. [DOI: 10.22175/mmb2019.0051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
48
|
Fu S, Corr B, Hamilton E, Burger R, Wenham R, Naumann R, Stagg R, Moore K. A phase Ib study of navicixizumab & weekly paclitaxel in heavily pre-treated platinum resistant ovarian, primary peritoneal or fallopian tube cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy285.159] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Wainberg Z, Strickler J, Gordon M, Barve M, Wang L, Yue H, Motwani M, Kasichayanula S, Naumovski L, Hamilton E. Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.233] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Pegram M, Hamilton E, Tan A, Storniolo A, Elgeioushi N, Marshall S, Abdullah S, Patel M. Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy048.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|